SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART
Open Access
- 23 August 2024
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 45, 101032
Abstract
No abstract availableKeywords
Funding Information
- Hjärt-Lungfonden
- Vetenskapsrådet
- Stiftelsen Bundy Academy
- Knut och Alice Wallenbergs Stiftelse
- Skånes universitetssjukhus
This publication has 25 references indexed in Scilit:
- Dapagliflozin in Patients With Heart Failure and Deterioration in Renal FunctionJACC, 2023
- Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPharmacological Research, 2022
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsThe Lancet, 2022
- Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trialAmerican Heart Journal, 2022
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) InhibitorsJACC: Basic To Translational Science, 2020
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008